10206-21-0 Usage
Description
This drug is similar to cephalothin, but after intravenous administration, higher peak serum levels are attained, and its serum half-life is
longer (Brogard et al., 1973a; Brogard et al., 1973b). However,
cephacetrile appears to have no clinical advantages over cephalothin,
as demonstrated in one comparative trial (Jackson et al., 1974). It has
most recently been available in Italy.
Chemical Properties
Pale Beige Solid
Originator
Celospor,Ciba Geigy,Switz.,1969
Uses
Different sources of media describe the Uses of 10206-21-0 differently. You can refer to the following data:
1. A cephalosporin antibiotic.
2. A cephalosporin antibiotic. Antibacterial.
Manufacturing Process
13.6 g (0.05 mol) of 7-aminocephalosporanic acid are taken up in a mixture
of 150 ml of methylene chloride and 19.5 ml of tributylamine (0.12 mol) and
at 0°C a solution of 8.4 g of cyanoacetylchloride (0.07 mol) in 100 ml of
methylene chloride is stirred in. The bath is then stirred for ? hour at 0°C
and for ? hour at 20°C, the reaction solution is evaporated under vacuum
and the residue taken up in 10% aqueous dipotassium hydrogenphosphate
solution. This aqueous phase is washed with ethyl acetate, acidified to pH 2.0
with concentrated hydrochloric acid and extracted with ethyl acetate.
After having been dried over sodium sulfate and evaporated under vacuum,
this extract gives as a solid residue 14.7 g of crude 7-cyanoacetylamino-cephalosporanic acid which is purified by chromatography on 30 times its own
weight of silica gel. The fractions eluted with chloroform plus acetone (7:3)
furnish a product which crystallizes from acetone plus ether in the form of
needles melting at 168° to 170°C with decomposition.
5.10 g (15 mmol) of 7-cyanoacetyl-aminocephalosporanic acid are suspended in 102 ml of distilled water and converted into the sodium salt by stirring in
dropwise 15 ml of N sodium hydroxide solution.
Therapeutic Function
Antibiotic
Antimicrobial activity
Its spectrum resembles that of cefalotin. Following an intramuscular
dose of 1 g, a peak plasma concentration around
15 mg/L is achieved at 1 h. About 25% is bound to plasma protein. Penetration into the CSF is limited. About 80% of
the drug is excreted in the urine, producing concentrations
in excess of 1 g/L, 25% of which is in the desacetylated form.
Clearance is depressed by probenecid and in renal failure.
Little is excreted in the bile.
Manifestations of hypersensitivity in patients not known
to be allergic to β-lactam antibiotics are common. It is no
longer used.
Check Digit Verification of cas no
The CAS Registry Mumber 10206-21-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,2,0 and 6 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 10206-21:
(7*1)+(6*0)+(5*2)+(4*0)+(3*6)+(2*2)+(1*1)=40
40 % 10 = 0
So 10206-21-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1
10206-21-0Relevant articles and documents
6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors
-
, (2008/06/13)
6-beta-Halopenicillanic acid 1,1-dioxides, physiologically acceptable salts thereof and esters thereof readily hydrolyzable; pharmaceutical compositions containing a 6-beta-halopenicillanic acid 1,1-dioxide, a physiologically acceptable salt thereof or an ester thereof readily hydrolyzable; and a method for enhancing the effectiveness of a beta-lactam antibiotic, using a 6-beta-halopenicillanic acid 1,1-dioxide, a physiologically acceptable salt thereof or an ester thereof readily hydrolyzable.
DERIVATIVES OF 6BETA-HYDROXYALKYLPENICILLANIC ACIDS AS BETA-LACTAMASE INHIBITORS
-
, (2008/06/13)
6beta-Hydroxyalkylpenicillanic acids and derivatives thereof as useful enhancers of the effectiveness of several beta-lactam antibiotics against many beta-lactamase producing bacteria, and 6beta-substituted penicillanic acid benzyl ester derivatives as useful intermediates leading to said agents which enhance the effectiveness of beta-lactam antibiotics
Process for preparing cephalosporines
-
, (2008/06/13)
A process for preparing cephalosporines in which a cephalosporanic derivative is treated with a polar solvent, then with an organic base to give a mixture which is cooled at a temperature lower than -25° C. A cyclic derivative of boron is added to the mixture and the temperature is increased to about 0° C. An intermediate compound is formed which by treatment first with an acylating agent and then with a mixture of water and alcohol provides a solution containing cephalosporines.
